Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The German AML Cooperative Group is inviting all experts to participate in the 16th International Symposium on Acute Leukemias (ISAL) which will be held in Munich, Germany on 19–22 February, 2017.

The scientific program will focus on basic research in acute leukemia while the following days of the meeting will concentrate on translational research and clinical studies.

ISAL 2017

The 16th International Symposium on Acute Leukemias (ISAL)
19–22 February 2017 | Munich, Germany

ISAL 2017

The 16th International Symposium on Acute Leukemias (ISAL)
19–22 February 2017 | Munich, Germany

The German AML Cooperative Group is inviting all experts to participate in the 16th International Symposium on Acute Leukemias (ISAL) which will be held in Munich, Germany on 19–22 February, 2017.

The scientific program will focus on basic research in acute leukemia while the following days of the meeting will concentrate on translational research and clinical studies.

Highlights from the International Symposium on Acute Leukemias (ISAL) 2017 in Munich 1:33
Highlights from the International Symposium on Acute Leukemias (ISAL) 2017 in Munich
Wolfgang Hiddemann • 20 Feb 2017
Progress in acute myeloid leukemia treatment – collaborating to develop targeted therapies 2:02
Progress in acute myeloid leukemia treatment – collaborating to develop targeted therapies
Wolfgang Hiddemann • 20 Feb 2017
Understanding the complexity of acute myeloid leukemia (AML) 2:30
Understanding the complexity of acute myeloid leukemia (AML)
Andrew Wei • 19 Feb 2017
The molecular heterogeneity of acute myeloid leukemia (AML) – new data and implications 4:57
The molecular heterogeneity of acute myeloid leukemia (AML) – new data and implications
Bob Löwenberg • 19 Feb 2017
The history of collaboration in acute promyelocytic leukemia (APL) research 1:36
The history of collaboration in acute promyelocytic leukemia (APL) research
Francesco Lo-Coco • 19 Feb 2017
The utility of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML) 2:18
The utility of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele • 19 Feb 2017
Developments in therapies for AML – chemotherapy, targeted therapy and immunotherapy 4:20
Developments in therapies for AML – chemotherapy, targeted therapy and immunotherapy
Hagop Kantarjian • 19 Feb 2017
Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 years 2:48
Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 years
Andrew Wei • 19 Feb 2017
Developing targeted therapies to combine with venetoclax in acute myeloid leukemia (AML) 1:32
Developing targeted therapies to combine with venetoclax in acute myeloid leukemia (AML)
Marina Konopleva • 19 Feb 2017
BiTES for the treatment of acute myeloid leukemia (AML) – results with AMG 330 in ex vivo study 1:44
BiTES for the treatment of acute myeloid leukemia (AML) – results with AMG 330 in ex vivo study
Marion Subklewe • 19 Feb 2017
The importance of finding strategies to prevent relapse of acute myeloid leukemia (AML) 1:22
The importance of finding strategies to prevent relapse of acute myeloid leukemia (AML)
Kristoffer Hellstrand • 19 Feb 2017
A new era of treatment for elderly acute myeloid leukemia (AML) patients? 1:21
A new era of treatment for elderly acute myeloid leukemia (AML) patients?
Hagop Kantarjian • 19 Feb 2017
Developments in prognostic factors of acute myeloid leukemia (AML) 1:42
Developments in prognostic factors of acute myeloid leukemia (AML)
Gert J. Ossenkoppele • 19 Feb 2017
Exploring combinatorial approaches in acute myeloid leukemia (AML) treatment 1:31
Exploring combinatorial approaches in acute myeloid leukemia (AML) treatment
Francesco Lo-Coco • 19 Feb 2017
Perspectives in AML treatment: targeting apoptosis without chemotherapy by using BH3-mimetics 3:15
Perspectives in AML treatment: targeting apoptosis without chemotherapy by using BH3-mimetics
Andrew Wei • 19 Feb 2017
Remission maintenance with histamine dihydrochloride (HDC)/IL-2 therapy in AML 1:17
Remission maintenance with histamine dihydrochloride (HDC)/IL-2 therapy in AML
Kristoffer Hellstrand • 19 Feb 2017

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals